qloolp

Thoughts, stories and ideas.

Latest

Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Merck.com - Merck.com

Groundbreaking News in Endometrial Cancer Treatment A recent study has made a significant breakthrough in the treatment of advanced or recurrent endometrial cancer. The Sacituzumab Gimantelax (Sac-TMT) antibody-drug conjugate (ADC) has been shown to improve both overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in patients who have

By Tornado